rb 6145 has been researched along with tirapazamine in 9 studies
| Studies (rb 6145) | Trials (rb 6145) | Recent Studies (post-2010) (rb 6145) | Studies (tirapazamine) | Trials (tirapazamine) | Recent Studies (post-2010) (tirapazamine) |
|---|---|---|---|---|---|
| 38 | 0 | 2 | 484 | 44 | 133 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (55.56) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Chaplin, DJ; Davis, P; Devkota, L; Gerberich, JL; Hamel, E; Kuch, B; MacDonough, MT; Mason, RP; Mondal, D; Pinney, KG; Ramirez, AJ; Shi, Z; Strecker, TE; Trawick, ML; Wang, Y; Winn, BA | 1 |
| Stratford, IJ | 1 |
| Chaplin, DJ | 1 |
| Adams, GE; Bremner, JC; Cole, S; Edwards, HS; Stratford, IJ | 1 |
| Adams, GE; Stratford, IJ | 1 |
| Baguley, BC; Lash, CJ; Li, AE; Rutland, M; Wilson, WR; Zwi, LJ | 1 |
| Lee, AE; Wilson, WR | 1 |
| Fitzmaurice, RJ; Lunt, SJ; Stratford, IJ; Telfer, BA; Williams, KJ | 1 |
| Ali, M; Babur, M; Bloomer, WD; Cawthorne, C; Julyan, PJ; Lunt, SJ; Papadopoulou, MV; Price, PM; Smigova, A; Stratford, IJ; Telfer, BA; Williams, KJ | 1 |
1 review(s) available for rb 6145 and tirapazamine
| Article | Year |
|---|---|
Bioreductive drugs in cancer therapy.
Topics: Animals; Antineoplastic Agents; Antioxidants; Cell Hypoxia; Humans; Misonidazole; Neoplasms; Nitroimidazoles; Prodrugs; Radiation-Sensitizing Agents; Tirapazamine; Triazines | 1992 |
8 other study(ies) available for rb 6145 and tirapazamine
| Article | Year |
|---|---|
Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.
Topics: A549 Cells; Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Hypoxia; Colchicine; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; NADPH-Ferrihemoprotein Reductase; Prodrugs; Stilbenes; Tubulin | 2020 |
Bioreductive therapy.
Topics: Antineoplastic Agents; Cell Hypoxia; Humans; Misonidazole; Nitroimidazoles; Oxidation-Reduction; Prodrugs; Radiation-Sensitizing Agents; Tirapazamine; Triazines | 1992 |
Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9.
Topics: Animals; Antineoplastic Agents; Aziridines; Cell Hypoxia; Cell Survival; Combined Modality Therapy; Dose-Response Relationship, Drug; Indolequinones; Indoles; Mice; Mice, Inbred C3H; Misonidazole; Neoplasm Transplantation; Neoplasms, Experimental; Nitroimidazoles; Prodrugs; Tirapazamine; Triazines | 1992 |
Bioreductive drugs for cancer therapy: the search for tumor specificity.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Nitric Oxide; Nitroimidazoles; Oxidation-Reduction; Photochemotherapy; Porfiromycin; Prodrugs; Tirapazamine; Triazines | 1994 |
Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Female; Mice; Mice, Inbred C3H; Nitrogen Mustard Compounds; Nitroimidazoles; Prodrugs; Regional Blood Flow; Serotonin; Tirapazamine; Triazines; Xanthenes; Xanthones | 1998 |
Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice.
Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Hypoxia; Light; Mice; Mice, Inbred C57BL; Nitroimidazoles; Oxidation-Reduction; Prodrugs; Radiation-Sensitizing Agents; Retina; Tirapazamine; Triazines | 2000 |
Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Female; Hypoxia; Mice; Mice, Inbred C3H; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Nitroimidazoles; Radiation-Sensitizing Agents; Sarcoma, Experimental; Tirapazamine; Treatment Outcome; Triazines | 2005 |
The hypoxia-selective cytotoxin NLCQ-1 (NSC 709257) controls metastatic disease when used as an adjuvant to radiotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Hypoxia; Cell Line, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Drug Evaluation, Preclinical; Imidazoles; Lung Neoplasms; Mice; Mice, Inbred C3H; Neoplasm Metastasis; Nitroimidazoles; Quinolines; Sarcoma; Tirapazamine; Triazines | 2010 |